NASDAQ · Biotechnology · USD
CollPlant Biotechnologies Ltd. (CLGN) Stock Analysis
CollPlant Biotechnologies Ltd. (CLGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CLGN Key Statistics
As of Oct 21, 2026Trading
- Open
- $3.80
- Previous Close
- $3.88
- Day's Range
- 3.55–3.81
- 52-Week Range
- 2.64–26.80
- Volume
- 9.65K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.76
Valuation
- Market Cap
- $7.39M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 23.25
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −9.33
Financials (FY)
- Revenue (FY)
- $2.37M+360.39%
- Net Income (FY)
- −$11.49M
- Shares Outstanding
- 1.89M
- 1-Year Return
- −84.16%
Dividend and dates
- Earnings Date
- November 25, 2026estimated
- Avg Volume
- 358.27K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CLGN closed at $3.76, −84.16% over 1 year.
CollPlant Biotechnologies Ltd. (CLGN) has a market capitalization of $7.39M.
In fiscal 2025, CLGN reported revenue of $2.37M.
CLGN Stock Return by Calendar Year
CollPlant Biotechnologies Ltd. (CLGN) return since Jan 2018: what $10,000 became
- 1 year
- $10,000 $1,584
- −84.16%
- 5 years
- $10,000 $188
- −98.12%
- Since Jan 2018
- $10,000 $420
- −95.80%
If you had invested $10,000 in CollPlant Biotechnologies Ltd. (CLGN) at the close on January 31, 2018, the earliest close on record here, it would have been worth $420 at the close on October 21, 2026: −95.80% in total, −30.49% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −73.18% |
| 2025 | −61.11% |
| 2024 | −43.66% |
| 2023 | −23.47% |
| 2022 | −48.96% |
| 2021 | +51.90% |
| 2020 | +88.95% |
| 2019 | +35.71% |
| 2018 | −53.07% |
As of October 21, 2026.
CLGN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $2.37M | −$11.49M | −484.6% |
| 2024 | $515.00K | −$16.61M | −3,225.0% |
| 2023 | $10.96M | −$7.02M | −64.0% |
| 2022 | $299.00K | −$16.93M | −5,660.5% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $2.37M | $1.54M | −$11.48M | −$11.49M | −484.6% |
| 2024 | $515.00K | −$1.11M | −$17.25M | −$16.61M | −3,225.0% |
| 2023 | $10.96M | $8.97M | −$7.51M | −$7.02M | −64.0% |
| 2022 | $299.00K | −$101.00K | −$17.10M | −$16.93M | −5,660.5% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
CLGN Valuation vs Biotechnology Median
Median of 608 stocks| Metric | CLGN | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 23.25 | 13.30 | 75% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT
YahooCollPlant Biotechnologies Announces Private Placement Of 989,301 Shares And Warrants To Purchase Up To 1,483,952 Shares At $3.74/Unit
BenzingaCollPlant Biotechnologies Unit LightSolver Files U.S. Provisional Patent Application For Expansion Of Its All-Optical, Laser-Based Computing Platform
BenzingaCOLLPLANT REPORTS 2026 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
YahooCollPlant Biotechnologies Q2 Adj. EPS $(1.69) Misses $(0.24) Estimate, Sales $108.000K Miss $1.466M Estimate
BenzingaLightSolver, a CollPlant Company, and HLRS Joint Research Demonstrated Photonic Computing Can significantly Accelerate Fundamental HPC Workloads
Yahoo
All 17 articles ↓Show fewer ↑
CollPlant Announces Publication Of Joint Research Conducted By Its Subsidiary LightSolver Showing Photonic Computing Advantage Over GPUs
BenzingaCollPlant Regains Compliance with Nasdaq Minimum Bid Price Requirement
YahooCollPlant Biotechnologies Regains Nasdaq Compliance
BenzingaCollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing - Slideshow
SeekingAlphaCollPlant Biotechnologies Ltd. (CLGN) Discusses Acquisition of Lightsolver and Strategic Entry Into High-Performance Photonic Computing Transcript
SeekingAlphaCollPlant to Host LightSolver Investor Webinar on September 17, 2026
YahooCOLLPLANT APPOINTS DR. RUTI BEN SHLOMI TO ITS BOARD OF DIRECTORS FOLLOWING CLOSING OF LIGHTSOLVER ACQUISITION
YahooCOLLPLANT COMPLETES ACQUISITION OF LIGHTSOLVER, ENTERING THE PHOTONIC COMPUTING SECTOR
YahooCOLLPLANT ANNOUNCES REVERSE SHARE SPLIT
YahooCollPlant Biotechnologies Board Approves 1-For-10 Reverse Share Split, Effective September 4
BenzingaCOLLPLANT IS ACQUIRING LIGHTSOLVER- ENTERS SUPERCOMPUTING AND PHOTONIC COMPUTING MARKETS
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B